Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
靶向母细胞性浆细胞样树突状细胞肿瘤 (BPDCN)
基本信息
- 批准号:10335170
- 负责人:
- 金额:$ 39.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAddressAllelesApoptosisApoptoticAreaBCL-2 ProteinBCL2 geneBiologicalBiological AssayBiological ModelsBiological Response Modifier TherapyBiologyBlastic plasmacytoid dendritic cell neoplasmBloodBone MarrowCancer BiologyCellsChemoresistanceClinicalClinical ResearchClinical TrialsComplexConfusionCutaneous InvolvementDNADNA sequencingDataDendritic CellsDependenceDiagnosisDiphtheria ToxinDiseaseFemaleFrequenciesFunctional disorderGNB1 geneGenesGeneticGenetic EngineeringGenetic ModelsGenetic TranscriptionGenetic studyGoalsHematologic NeoplasmsHematopoiesisHeterotrimeric G Protein SubunitHumanIL3RA geneIncidenceInterleukinsKnowledgeLaboratoriesLeukemic CellLeukemic Natural Killer CellLymphomaMalignant - descriptorMalignant NeoplasmsMeasuresMedicalMedicineMissionModelingMusMutateMutationNCAM1 geneNamesNatureNeoplasmsOncogenesOntologyOrphanOutcomeOutputPathogenesisPathway interactionsPatientsPhenotypePublic HealthRNA SplicingRecurrenceRefractoryRelapseResearchResistanceRoleSamplingSex BiasSignal TransductionSiteSomatic MutationSpliceosomesSystemTestingTherapeuticTherapeutic StudiesTransplantationTumor Suppressor ProteinsUnited States National Institutes of HealthValidationWomanX ChromosomeX Inactivationbasecancer typecell transformationchemotherapyclinically relevantclinically significantcohorteffective therapyexomeexome sequencingimprovedimproved outcomein vivoin vivo Modelinhibitorinnovationinsightloss of function mutationlymph nodesmRNA Precursormalemenmimeticsmutantnoveloptimal treatmentspatient derived xenograft modelprematuresexstandard carestem cellstargeted sequencingtherapeutic targettranscriptometreatment responsetreatment strategytumor
项目摘要
Project Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan hematologic malignancy that is clinically
aggressive and fatal in most patients within one year of diagnosis. The disease pathogenesis is largely
unknown, there is no standard treatment, and patients with BPDCN have a clear unmet medical need. The
long-term goal is to improve outcomes in BPDCN by deeper understanding of disease biology. DNA
sequencing in BPDCN revealed a high frequency of mutations in RNA splicing factors, with particular
enrichment in loss-of-function mutations in ZRSR2 compared to other cancers. Functional assessment of
patient tumors found that BPDCN is uniquely dependent on the anti-apoptotic protein BCL2 and is highly
sensitive to treatment with the BH3 mimetic venetoclax. New genetically engineered models of dendritic cell
leukemia and BPDCN patient-derived xenografts offer a unique opportunity to test the contribution of disease
alleles to splicing abnormalities and therapeutic response. The overall objective of this application is to test the
hypothesis that genetic alterations associated with BPDCN contribute to dendritic cell transformation and
create targetable vulnerabilities. Guided by strong preliminary data from the applicant's laboratory and an
established network of expert collaborators, this central hypothesis will be tested by pursuing two specific aims:
1) Determine how ZRSR2 mutation promotes dendritic cell transformation; and 2) Identify factors that generate
unique apoptotic dependencies in BPDCN. Under the first Aim, the applicant will use genetic models of ZRSR2
deficiency in dendritic cells and BPDCNs to determine how splicing mutations alter the transcriptome and
cause transformation of the dendritic lineage. They will also test how mutations in ZRSR2, a gene located on
the X chromosome that escapes X-inactivation in female cells, contributes to the male bias of BPDCN and
sensitizes to splicing modulator therapy. Under the second Aim, the mechanisms of BCL2 dependence in
normal and malignant dendritic cells will be investigated in human and mouse hematopoiesis. Adaptations to
chemotherapy in BPDCN will be measured to determine if BCL2 inhibition can overcome chemoresistance,
which is the major barrier to improved outcomes in patients. The approach is innovative by making use of
novel model systems and samples from BPDCN patients on active clinical trials. The downstream effects of
ZRSR2 mutations on BPDCN and male cancer predominance have not been clarified, and the mechanisms of
protection from apoptosis in normal and malignant dendritic cells are unknown. The proposed research is
significant, because it is expected to define the biological role of clinically-relevant mutations in an
understudied and highly fatal disease. The expected output for the proposed research is that the knowledge
gained will be immediately clinically significant for patients with BPDCN because it will inform new treatment
strategies in a cancer that is currently lacking in significant biological and therapeutic insight.
项目摘要
母细胞性浆细胞样树突状细胞肿瘤(BPDCN)是一种罕见的血液系统恶性肿瘤,
大多数患者在诊断后一年内具有侵袭性和致命性。疾病的发病机制主要是
未知,没有标准治疗,BPDCN患者有明确的未满足的医疗需求。的
长期目标是通过更深入地了解疾病生物学来改善BPDCN的结果。DNA
BPDCN的测序揭示了RNA剪接因子的高频率突变,特别是
与其他癌症相比,ZRSR 2中功能缺失突变的富集。功能评估
患者肿瘤发现,BPDCN是唯一依赖于抗凋亡蛋白BCL 2和高度依赖于抗凋亡蛋白BCL 2。
对BH 3模拟物维奈托克治疗敏感。树突状细胞的新基因工程模型
白血病和BPDCN患者来源的异种移植物提供了一个独特的机会来测试疾病的贡献
等位基因与剪接异常和治疗反应的关系。此应用程序的总体目标是测试
假设与BPDCN相关的遗传改变有助于树突状细胞转化,
创建可攻击的漏洞。根据申请人实验室的初步数据和
建立了专家合作者网络,将通过追求两个具体目标来检验这一中心假设:
1)确定ZRSR 2突变如何促进树突状细胞转化;和2)确定产生ZRSR 2突变的因素。
BPDCN中独特的凋亡依赖性。根据第一个目标,申请人将使用ZRSR 2的遗传模型
树突状细胞和BPDCN的缺陷,以确定剪接突变如何改变转录组,
导致树突细胞的转化。他们还将测试ZRSR 2基因的突变是如何发生的,
在雌性细胞中逃避X失活的X染色体,有助于BPDCN的雄性偏好,
对剪接调节剂疗法敏感。在第二个目标下,BCL 2依赖性的机制,
将在人和小鼠造血中研究正常和恶性树突细胞。适应性
将测量BPDCN中的化学疗法以确定BCL 2抑制是否可以克服化学抗性,
这是改善患者预后的主要障碍。该方法是创新的,利用了
新的模型系统和来自活跃临床试验的BPDCN患者的样品。的下游效应
BPDCN上的ZRSR 2突变和男性癌症优势尚未阐明,并且ZRSR 2突变的机制在BPDCN上是不稳定的。
在正常和恶性树突细胞中对凋亡的保护是未知的。拟议的研究是
重要的是,因为它预计将定义临床相关突变的生物学作用,
研究不足的高致命性疾病。拟议研究的预期产出是,
对于BPDCN患者,获得的信息将立即具有临床意义,因为它将告知新的治疗方法
这是目前缺乏重要生物学和治疗见解的癌症治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew A Lane其他文献
Andrew A Lane的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew A Lane', 18)}}的其他基金
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
靶向母细胞性浆细胞样树突状细胞肿瘤 (BPDCN)
- 批准号:
10332257 - 财政年份:2018
- 资助金额:
$ 39.7万 - 项目类别:
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
靶向母细胞性浆细胞样树突状细胞肿瘤 (BPDCN)
- 批准号:
10784797 - 财政年份:2018
- 资助金额:
$ 39.7万 - 项目类别:
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
靶向母细胞性浆细胞样树突状细胞肿瘤 (BPDCN)
- 批准号:
9420186 - 财政年份:2018
- 资助金额:
$ 39.7万 - 项目类别:
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
靶向母细胞性浆细胞样树突状细胞肿瘤 (BPDCN)
- 批准号:
10079473 - 财政年份:2018
- 资助金额:
$ 39.7万 - 项目类别:
Targeting Chromatin Modifications in Leukemia with Trisomy 21
利用 21 三体靶向白血病中的染色质修饰
- 批准号:
9198490 - 财政年份:2014
- 资助金额:
$ 39.7万 - 项目类别:
Targeting Chromatin Modifications in Leukemia with Trisomy 21
利用 21 三体靶向白血病中的染色质修饰
- 批准号:
8813538 - 财政年份:2014
- 资助金额:
$ 39.7万 - 项目类别:
Targeting Chromatin Modifications in Leukemia with Trisomy 21
利用 21 三体靶向白血病中的染色质修饰
- 批准号:
8617463 - 财政年份:2014
- 资助金额:
$ 39.7万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 39.7万 - 项目类别:
Research Grant